Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Otolaryngol Head Neck Surg. 2013 Jun;148(6):965-73. doi: 10.1177/0194599813479556. Epub 2013 Feb 27.
We investigated the expression and clinical significance of activin receptor-like kinase 1 (ACVRL1) in patients with head and neck squamous cell carcinoma (HNSCC).
Case series with chart review.
Academic Institute of Otolaryngology, Kaohsiung, Taiwan.
Patients diagnosed with HNSCC (n = 169) underwent surgical resection followed by radiotherapy and/or chemotherapy for aggressive tumors between November 2000 and March 2004. ACVRL1 expression was assessed using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemistry approaches.
High levels of ACVRL1 expression were significantly correlated with advanced T classification (P < .001), positive N classification (P = .002), advanced TNM stage (P < .001), lymphovascular invasion (P < .001), and extracapsular spread of lymph node metastasis (P = .021). A poor 5-year overall survival rate was correlated with high ACVRL1 expression (P = .0048), advanced T classification (P = .0075), positive N classification (P = .0024), advanced TNM stage (P = .0077), and extracapsular spread of lymph node (P = .0002), but a multivariate analysis using the Cox regression model revealed that the only independent prognostic factors for survival were ACVRL1 expression (P = .043; odds ratio [OR], 1.635; 95% confidence interval [CI], 1.017-2.629) and extracapsular spread of lymph node metastasis (P = .003; OR, 2.052; 95% CI, 1.270-3.315).
A high level of ACVRL1 expression in tumor tissue is significantly correlated with advanced T classification, positive N classification, advanced TNM stage, and poorer prognosis.
我们研究了激活素受体样激酶 1（ACVRL1）在头颈部鳞状细胞癌（HNSCC）患者中的表达及其临床意义。
病例系列，结合图表回顾。
台湾高雄市学术耳鼻喉研究所。
2000 年 11 月至 2004 年 3 月，169 例诊断为 HNSCC 的患者接受了手术切除，随后接受了放疗和/或化疗。采用定量逆转录聚合酶链反应（qRT-PCR）和免疫组织化学方法评估 ACVRL1 的表达。
高水平的 ACVRL1 表达与较高的 T 分类（P<0.001）、阳性 N 分类（P=0.002）、较晚的 TNM 分期（P<0.001）、淋巴血管侵犯（P<0.001）和淋巴结转移的包膜外扩散（P=0.021）显著相关。5 年总生存率与高 ACVRL1 表达相关（P=0.0048），与较高的 T 分类（P=0.0075）、阳性 N 分类（P=0.0024）、较晚的 TNM 分期（P=0.0077）和淋巴结转移的包膜外扩散（P=0.0002）相关。然而，使用 Cox 回归模型的多变量分析显示，生存的唯一独立预后因素是 ACVRL1 表达（P=0.043；优势比[OR]，1.635；95%置信区间[CI]，1.017-2.629）和淋巴结转移的包膜外扩散（P=0.003；OR，2.052；95%CI，1.270-3.315）。
肿瘤组织中 ACVRL1 表达水平高与较高的 T 分类、阳性 N 分类、较晚的 TNM 分期和较差的预后显著相关。
